<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0215642.ref006">
 <label>6</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>González-González</surname>
   <given-names>E</given-names>
  </name>, 
  <name>
   <surname>Alvarez</surname>
   <given-names>MM</given-names>
  </name>, 
  <name>
   <surname>Márquez-Ipiña</surname>
   <given-names>AR</given-names>
  </name>, 
  <name>
   <surname>Trujillo-de Santiago</surname>
   <given-names>G</given-names>
  </name>, 
  <name>
   <surname>Rodríguez-Martínez</surname>
   <given-names>LM</given-names>
  </name>, 
  <name>
   <surname>Annabi</surname>
   <given-names>N</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead</article-title>. 
  <source>Crit Rev Biotechnol</source>. Taylor &amp; Francis; 
  <year>2017</year>;
  <volume>37</volume>: 
  <fpage>53</fpage>–
  <lpage>68</lpage>. 
  <pub-id pub-id-type="doi">10.3109/07388551.2015.1114465</pub-id>
  <?supplied-pmid 26611830?>
  <pub-id pub-id-type="pmid">26611830</pub-id>
 </mixed-citation>
</ref>
